-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Astellas announced that the European Commission has approved a new indication for Xtandi: for the treatment of adult patients with metastatic hormone-sensitive prostate cancer.
This approval is based on data from the pivotal Phase 3 ARCHS study (NCT02677896).
The results showed that the study reached the primary endpoint of imaging progression-free survival (rPFS): Compared with the placebo+ADT regimen group, the Xtandi+ADT regimen group significantly reduced the risk of radiological progression or death by 61% (HR=0.
Original source: Astellas' XTANDI (enzalutamide) approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer